IPAMORELIN 5MG

£22.00

Ipamorelin is a specialised research peptide used in scientific investigation of growth hormone secretagogue activity, selective ghrelin receptor (GHS-R1a) signalling, and neuroendocrine regulatory pathways.

Batch tested Purity: ≥ 99 % (HPLC, typical)
CAS Number: 170851-70-4
Molecular Formula: C₃₈H₄₉N₉O₅

Guaranteed Safe Checkout

ALL ARTICLES AND PRODUCT INFORMATION PROVIDED ON THIS WEBSITE ARE FOR INFORMATIONAL AND EDUCATIONAL PURPOSES ONLY.

The products offered on this website are furnished for in-vitro studies only. In-vitro studies are performed outside of the body. These products are not medicines or drugs and have not been approved to prevent, treat or cure any medical condition, ailment or disease. Bodily introduction of any kind into humans or animals is strictly forbidden.

Reconstitution

Use bacteriostatic water. Add solvent slowly along vial wall. Do not shake gently swirl.

Cold Chain

Store lyophilised at 2–8°C. Once reconstituted, keep at 2–8°C and use within 28 days.

Certificate of Analysis

CoA available on request for each batch. HPLC and MS data provided.

Description

Batch HPLC tested at 98.5%+ purity.
Store frozen long term or refrigerated when ready for use.
Sold for research purposes only.
Contact us for wholesale orders.

Ipamorelin

Synonyms / Designations: Ipamorelin, Ipamorelin Acetate, NNC 26-0161, Ipamorelin pentapeptide
CAS Number: 170851-70-4
Molecular Formula: C₃₈H₄₉N₉O₅
Molecular Weight: ~711.85 g/mol
Peptide Sequence: Aib-His-D-2-Nal-D-Phe-Lys-NH₂
Peptide Classification: Synthetic growth hormone secretagogue; selective ghrelin receptor agonist
Purity: ≥99% (HPLC, typical)
Appearance: White to off-white lyophilised powder
Storage: Desiccated, protected from light, stored at –20 °C
Solubility: Soluble in sterile water and buffered aqueous solutions

Description & Mechanism

Ipamorelin is a synthetic pentapeptide growth hormone secretagogue derived from GHRP-1 through structural optimisation. It was the first selective growth hormone-releasing peptide (GHRP) receptor agonist developed, demonstrating selectivity similar to that of growth hormone-releasing hormone (GHRH) for stimulating growth hormone release.

In biochemical and cellular research systems, Ipamorelin acts as an agonist at the ghrelin/growth hormone secretagogue receptor (GHSR-1a) expressed on pituitary somatotroph cells. Unlike earlier GHRP compounds such as GHRP-6 and GHRP-2, Ipamorelin exhibits a distinct selectivity profile. Experimental studies have demonstrated that it does not release adrenocorticotropic hormone (ACTH) or cortisol at growth hormone-stimulating concentrations. This selectivity makes Ipamorelin a valuable research tool for investigating GH secretion pathways independently of hypothalamic-pituitary-adrenal (HPA) axis activation. In animal models, Ipamorelin has been reported to induce longitudinal bone growth in a dose-dependent manner under controlled experimental conditions.

Applications in Research

Investigation of GHSR-1a receptor binding, selectivity, and signalling pathways.
Study of growth hormone secretagogue mechanisms independent of HPA axis activation.
Research into pituitary somatotroph function and GH release dynamics.
In vitro and in vivo comparison with other GHRP compounds (GHRP-2, GHRP-6, Hexarelin).
Models examining GH/IGF-1 axis regulation and bone growth signalling.
Use as a selective reference compound in neuroendocrine and peptide signalling research.

Handling, Reconstitution & Stability

Weigh under dry conditions; peptide is hygroscopic.
Reconstitute in sterile water or an appropriate buffered aqueous solution depending on assay requirements.
Avoid vigorous agitation during dissolution.
Filter sterilise if required (e.g. 0.22 µm) immediately prior to use.
Aliquot and store reconstituted solutions at –20 °C (or lower) to minimise degradation.
Avoid repeated freeze–thaw cycles.

Precautions & Notes

Experimental behaviour of Ipamorelin is influenced by receptor expression, concentration, and exposure duration.
Unlike GHRP-6 and GHRP-2, Ipamorelin does not stimulate ACTH or cortisol release at GH-stimulating concentrations.
Buffer composition, pH, and ionic strength may affect peptide stability and assay performance.
Appropriate controls are recommended to distinguish receptor-specific from non-specific effects.
Intended strictly for laboratory research use; not for human or veterinary application.

References

Raun, K. et al. Ipamorelin, the first selective growth hormone secretagogue. European Journal of Endocrinology, 1998.
https://pubmed.ncbi.nlm.nih.gov/9849822/
Sinha, D. K. et al. Beyond the androgen receptor: the contribution of growth hormone secretagogues to changes in body composition. Growth Hormone & IGF Research, 2020.
https://pmc.ncbi.nlm.nih.gov/articles/PMC7108996/
Johansen, P. B. et al. Ipamorelin, a new growth-hormone-releasing peptide, induces longitudinal bone growth in rats. Growth Hormone & IGF Research, 1999.
https://pubmed.ncbi.nlm.nih.gov/10373343/

Keywords: Ipamorelin, Ipamorelin Acetate, NNC 26-0161, Growth Hormone Secretagogue, GHSR-1a Agonist, Ghrelin Receptor Agonist, Selective GHRP, Synthetic Peptide, Neuroendocrine Research.